Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
N Engl J Med. 2023.
PMID: 37952131
Clinical Trial.
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lincoff AM, Marso SP, Fries TM, Plutzky J, Ryan DH; SELECT Study Group.
Lingvay I, et al. Among authors: hardt lindberg s.
Obesity (Silver Spring). 2023 Jan;31(1):111-122. doi: 10.1002/oby.23621. Epub 2022 Dec 10.
Obesity (Silver Spring). 2023.
PMID: 36502289
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite